Physician profile
Katheryn Smith
NPI 1659377752
$1,029.69
in general payments reported to CMS, 2019-2025
12 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.16 · 2023: $406 · 2024: $90.72 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $326.75 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $185.62 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $133.78 | 2023-2025 | Auvelity |
| Neurelis, INC. | $72.73 | 2023 | Valtoco |
| Mylan Specialty L.P. | $70.85 | 2024 | Yupelri |
| Abbvie INC. | $66.91 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $63.61 | 2023 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $42.23 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $23.64 | 2023 | Invega Trinza, Invega Sustenna |
| Lundbeck LLC | $15.07 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.56 | 2025 | Xifaxan |
| Neurocrine Biosciences, INC. | $13.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katheryn Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.